Greg Jones
Overview
Explore the profile of Greg Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
655
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McKelvey B, Andrews H, Baehner F, Chen J, Espenschied C, Fabrizio D, et al.
Diagnostics (Basel)
. 2024 May;
14(9).
PMID: 38732326
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development. However, the heterogeneity in ctDNA...
2.
Lynce F, Mainor C, Donahue R, Geng X, Jones G, Schlam I, et al.
Nat Commun
. 2024 May;
15(1):3957.
PMID: 38730268
No abstract available.
3.
Lynce F, Mainor C, Donahue R, Geng X, Jones G, Schlam I, et al.
Nat Commun
. 2024 Mar;
15(1):2691.
PMID: 38538574
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the...
4.
Lynce F, Mainor C, Donahue R, Geng X, Jones G, Schlam I, et al.
medRxiv
. 2023 Dec;
PMID: 38105958
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the...
5.
van Dorp J, Pipinikas C, Suelmann B, Mehra N, van Dijk N, Marsico G, et al.
Nat Med
. 2023 Jul;
30(1):304.
PMID: 37460757
No abstract available.
6.
van Dorp J, Pipinikas C, Suelmann B, Mehra N, van Dijk N, Marsico G, et al.
Nat Med
. 2023 Feb;
29(3):588-592.
PMID: 36732628
Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response (pCR) rates with preoperative ipilimumab plus nivolumab in stage III urothelial cancer (UC). In cohort 2, the...
7.
Mahmood K, Jampani P, Clarke J, Wolf S, Wang X, Wahidi M, et al.
Chest
. 2023 Jan;
164(1):252-261.
PMID: 36693563
Background: Pleural cytology is currently used to assess targetable mutations in patients with advanced lung adenocarcinoma. However, it is fraught with low diagnostic yield. Research Question: Can pleural cell-free DNA...
8.
Wilgucki M, Yeung V, Ho G, Bravo Montenegro G, Jones G, Reuss J, et al.
JTO Clin Res Rep
. 2022 Oct;
3(10):100396.
PMID: 36188633
Osimertinib, a third-generation tyrosine kinase inhibitor, is the frontline standard in the treatment of metastatic -mutant NSCLC. Although osimertinib is effective, disease progression occurs in virtually all patients, mediated by...
9.
Breadner D, Vincent M, Correa R, Black M, Warner A, Sanatani M, et al.
Lung Cancer
. 2022 Feb;
165:145-151.
PMID: 35124411
Introduction: Blood-based liquid biopsies examining circulating tumour DNA (ctDNA) have increasing applications in non-small cell lung cancer (NSCLC). Limitations in sensitivity remain a barrier to ctDNA replacing tissue-based testing. We...
10.
Golledge J, Arnott C, Moxon J, Monaghan H, Norman R, Morris D, et al.
Trials
. 2021 Dec;
22(1):962.
PMID: 34961561
Background: Multiple observational studies have associated metformin prescription with reduced progression of abdominal aortic aneurysm (AAA). The Metformin Aneurysm Trial (MAT) will test whether metformin reduces the risk of AAA...